Our overall objective with this study is firstly to provide a comprehensive assessment of intestinal permeability, mucosal barrier function using existing biomarkers and secondly to explore novel biomarkers for measuring intestinal permeability in patients with constipation predominant Irritable Bowel Syndrome (IBS-C).
In order to determine the differences in permeability in IBS-C in comparison with healthy volunteers, the following will be determined: differences in in vivo small intestinal and colonic permeability, differences in small intestinal and colonic mucosal barrier function, differences in effects of fecal supernatants on barrier function of T84 monolayers, and differences in novel biomarkers for intestinal permeability
Study Type
OBSERVATIONAL
Enrollment
39
Saccharide excretion was compared between IBS-C and healthy volunteers
Duodenal biopsies were collected from IBS-C and healthy volunteers
Colonic biopsies were collected from IBS-C and healthy volunteers
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Lactulose:C13 Mannitol Excretion Ratio 8-24hrs.
In vivo measurement of intestinal permeability using 13C mannitol \& lactulose was used. High performance liquid chromatography-tandem mass spectrometry was used to measure concentrations calculated using the overall urine volume excreted in each interval. Concentrations of 13C adjusted for the % of 13C in 12C mannitol (4.98% of 12C mannitol excreted was subtracted from 13C mannitol values; determined by analyzing replicate samples of control urine). All lactulose or 13C mannitol concentrations 8-24hr post-ingestion were used to determine colonic permeability. Lactulose to 13C mannitol excretion ratios, as a measure of dose of saccharide administered, were calculated.
Time frame: 8-24 hr post test-dose administration
Lactose:C13 Mannitol Excretion Ratio 0-2hours
Time frame: 0-2 hr post-test dose administration
Baseline Transmucosal Resistance (TMR) of Duodenal Mucosa
Time frame: Baseline
Cumulative FITC-Dextran (4kDa) Concentration Across Duodenal Mucosa
This is not a pharmacokinetic or pharmacodynamic measure. Hence only one time assessment is made 3 hours after FITC-Dextran (4kDa) administration.
Time frame: 3 hours post FITC-Dextran (4kDa) administration
Rate of FITC-Dextran (4kDa) Flux Across Duodenal Mucosa
This is not a pharmacokinetic or pharmacodynamic measure. Hence only one time assessment is made 3 hours after FITC-Dextran (4kDa) administration.
Time frame: Over 3 hours post FITC-Dextran (4kDa) administration
Baseline Transmucosal Resistance (TMR) of Colonic Mucosa
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cumulative FITC-Dextran (4kDa) Concentration Across Colonic Mucosa
Time frame: 3 hours post FITC-Dextran (4kDa) administration
Rate of FITC-Dextran (4kDa) Flux Across Colonic Mucosa
Time frame: Over 3 hours post FITC-Dextran (4kDa) administration
Cumulative E.Coli Bio- Particle K12 Concentration Across Duodenal Mucosa
Time frame: 3 hours post E.coli Bio- Particle administration
Rate of E.Coli Bio- Particle K12 Flux Across Duodenal Mucosa
Time frame: Over 3 hours post E.coli Bio- Particle administration
Cumulative E.Coli Bio- Particle K12 Concentration Across Colonic Mucosa
Time frame: 3 hours post E.coli Bio- Particle administration
Rate of E.Coli Bio- Particle K12 Flux Across Colonic Mucosa
Time frame: Over 3 hours post E.coli Bio- Particle administration
Duodenal Impedance
Time frame: Baseline
Mean Serum Endotoxin (Bacterial LPS) Levels
Time frame: Fasting, one time measurement after 8 hours